UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032829 |
|---|---|
| Receipt number | R000037238 |
| Scientific Title | Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort Extension |
| Date of disclosure of the study information | 2018/06/01 |
| Last modified on | 2020/11/25 22:45:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry
- Rivaroxaban cohort Extension
Acronym
JACRE-REx
Scientific Title
Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry
- Rivaroxaban cohort Extension
Scientific Title:Acronym
JACRE-REx
Region
| Japan |
Condition
Condition
Patients enrolled in [the previous study] who have not declared refusal to participation in this study according to an opt-out policy.
[The previous study]
Patients with nonvalvular atrial fibrillation [NVAF] who undergo catheter ablation.
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of rivaroxaban, an oral factor Xa inhibitor, in patients with NVAF during the perioperative period of catheter ablation by retrospectively following up patients until the late postoperative period.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The combination of thromboembolism and serious bleeding during the late postoperative period after one month from catheter ablation.
- Thromboembolism: including transient ischemic attack, cerebral infarction, and other kinds of systemic embolism.
- Serious bleeding
Key secondary outcomes
Occurrence (recurrence) of atrial fibrillation during the late postoperative period after one month from catheter ablation
Presence or absence of repeated ablation during the late postoperative period after one month from catheter ablation and its details
Stroke (ischemic)/TIA during the late postoperative period after one month from catheter ablation
Stroke (hemorrhagic) during the late postoperative period after one month from catheter ablation
Cardiovascular events during the late postoperative period after one month from catheter ablation
Serious bleeding during the late postoperative period after one month from catheter ablation
Not serious but clinically significant bleeding during the late postoperative period after one month from catheter ablation
Presence or absence of discontinuation of anticoagulant therapy during the late postoperative period after one month from catheter ablation
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients must meet all of the following conditions to be eligible for the study.
1] Diagnosis of nonvalvular atrial fibrillation [NVAF].
NVAF refers to atrial fibrillation without history of rheumatic mitral valve disease, prosthetic valve, or mitral valve repair.
2] Undergoing ablation therapy [radiofrequency ablation only] for the treatment of atrial fibrillation.
3] Receiving rivaroxaban for at least 3 weeks by the time of hospitalization for catheter ablation.
4] Age 20years and older at providing consent.
5] Written informed consent must be obtained from the patient, unless the following condition does not apply. If, upon approval by the Ethics Review Committee, information on the study has been properly disclosed to the target patients through means such as poster presentations in the study site, obtaining written informed consent can be exempted so that the patient will be excluded from the study only when she/he declares refusal to enrollment in the study.
Key exclusion criteria
Patients will be excluded from the study if any of the following conditions apply.
1] Contraindication to ablation therapy for the treatment of atrial fibrillation [e.g., due to a preoperative transesophageal echocardiography, CT, or MRI finding of a thrombus in the left atrium/left atrial appendage].
2] Development of thromboembolism or myocardial infarction within 2 months before enrollment.
3] Contraindication to Rivaroxaban.
4] For a study site that is allowed to omit the procedure of obtaining written informed consent, a patient who declares refusal to enrollment in the study will be excluded.
5] Current participation in another interventional clinical study.
6] The investigator's judgement that the patient will be inappropriate for participation in the study.
Target sample size
1118
Research contact person
Name of lead principal investigator
| 1st name | Ken |
| Middle name | |
| Last name | Okumra |
Organization
Saiseikai Kumamoto Hospital
Division name
Cardiovascular medicine, Division of Arrhythmia treatment category
Zip code
861-4193
Address
5-3-1,Chikami Minami-Ku Kumamoto-City Kumamoto,Japan
TEL
096-351-8000
okumura@hirosaki-u.ac.jp
Public contact
Name of contact person
| 1st name | Akiko |
| Middle name | |
| Last name | Fujihiro |
Organization
A2 Healthcare Corporation
Division name
Clinical Development Promotion Dept.
Zip code
112
Address
1-4-1,Koishikawa,Bunkyo-Ku, Tokyo, JAPAN
TEL
03-3830-1075
Homepage URL
JACRE_Ex@a2healthcare.com
Sponsor or person
Institute
Reimeikyo
Institute
Department
Personal name
Funding Source
Organization
Bayer Yakuhin,Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Saiseikai Kumamoto Hospital
Address
5-3-1,Chikami Minami-Ku Kumamoto-City Kumamoto,Japan
Tel
096-351-8000
JACRE_Ex@a2healthcare.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 06 | Month | 01 | Day |
Related information
URL releasing protocol
https://www.sciencedirect.com/science/article/abs/pii/S0914508720302999
Publication of results
Published
Result
URL related to results and publications
https://www.sciencedirect.com/science/article/abs/pii/S0914508720302999
Number of participants that the trial has enrolled
823
Results
Long-term incidence of thromboembolism was extremely low in patients with AF treated with CA, while that of major bleeding was not necessarily low.
Results date posted
| 2020 | Year | 11 | Month | 17 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Data of 975 patients(rivaroxaban,n=823;warfarin,n=152)were collected from 27 institutes.Patient population had mean age 63.7+-10.3 years,710(72.8%)males,mean CHA2DS2-VASc score 1.9+-1.5,and mean follow-up period 28.7+-12.7 months after the index procedure.Anticoagulants were continued in 496(50.9%)patients during the follow-up.
Participant flow
We established a prospective registry, called the JACRE registry, for patients on rivaroxaban or warfarin administration who received CA for AF. The outcomes up to 30 days following the procedure were reported previously. The present study involved a longer follow-up of patients enrolled in this registry to evaluate long-term anticoagulation strategies and clinical outcomes.
Adverse events
Thromboembolism occurred in 3 patients, hemorrhagic stroke in 5, and major bleeding events in 9 (annualized event rate, 0.13%, 0.22%, and 0.40% per patient-year, respectively).
Outcome measures
Composite of thromboembolism and severe bleeding events after 1 month of catheter ablation treatment.
Thromboembolism; transient ischemic attack, stroke, and other systemic embolism
Serious bleeding
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 04 | Month | 19 | Day |
Date of IRB
| 2018 | Year | 05 | Month | 30 | Day |
Anticipated trial start date
| 2018 | Year | 06 | Month | 15 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2019 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2019 | Year | 04 | Month | 30 | Day |
Date analysis concluded
| 2019 | Year | 06 | Month | 26 | Day |
Other
Other related information
In VENTURE-AF study, post-ablation incidences of thromboembolism and bleeding events in patients treated with rivaroxaban were reported not to differ from those treated with warfarin. In a double-blind study ROCKET-AF, rivaroxaban, an oral factor Xa inhibitor, was shown to be non-inferior to warfarin for prophylactic effects against NVAF-related <stroke and systemic embolism>.
Management information
Registered date
| 2018 | Year | 06 | Month | 01 | Day |
Last modified on
| 2020 | Year | 11 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037238
